Morgan Stanley lowered the firm’s price target on BioMarin (BMRN) to $96 from $97 and keeps an Overweight rating on the shares. The firm notes in an earnings preview that for Q2 its estimates are in line with the Street on revenues, but further out its sees BioMarin having under-appreciated revenue potential.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Pharmaceutical: Undervalued Stock with Promising Growth Catalysts and Positive Outlook
- BioMarin’s BMN 349 Study: A Potential Game-Changer in Genetic Disorder Treatment
- BioMarin price target raised to $113 from $108 at JPMorgan
- BioMarin’s BMN 349 Study: A New Frontier in Genetic Mutation Treatment
- BioMarin assumed with an Overweight at Morgan Stanley